Bristol Keeps Focus On Opdivo In Lung Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
Now that the PD-1 inhibitor has a melanoma approval under its belt, Bristol-Myers is moving full steam ahead with the development of Opdivo with 11 lung cancer clinical trials ongoing or planned.